Mucomixx is a food supplement containing Levilactobacillus brevis* DSM27961 for oral hygiene.
Ingredients
Mucomixx contains at least 1 billion Levilactobacillus brevis DSM 27961 per lozenge. The package contains 20 lozenges into a convenient vial.
*Lactobacillus brevis has been reclassified as Levilactobacillus brevis according to a study published by Zheng and colleagues (Zheng et al., Int J Syst Evol Microbiol 2020 Apr 15. doi: 10.1099/ijsem.0.004107).
News and Events
Mucomixx at the IV ATASIO National Congress
At the beginning of February the IV National Congress ATASIO (Academy of Advanced Technologies in Oral Hygiene Sciences) was held in Rome at the Department of Odontostomatological Sciences
Mucomixx will be present at the Expodental Meeting in Rimini, from September 9 to 11
Come and visit our Italian distributor Biosphaera at the stand Infodent. Expodental Meeting, the most important appointment of the year for Italian dental professionals. LOCATION/ Rimini Fiera (RN) PAVILIONS/
The role of inflammation and genetics in periodontal disease
Loos, B. G. & Van Dyke, T. E. Abstract Patients with periodontitis show inflammatory destruction of the supporting tissues around the teeth. Loss of connective tissue and collagen
Lactobacillus brevis CD2 for Prevention of Oral Mucositis in Patients With Head and Neck Tumors: A Multicentric Randomized Study.
De Sanctis, V., Belgioia, L., Cante, D., La Porta, M. R., Caspiani, O., Guarnaccia, R., et al. Abstract BACKGROUND - Oropharyngeal mucositis occurs in virtually all patients with
Lactobacillus brevis CD2 lozenges prevent oral mucositis in patients undergoing high dose chemotherapy followed by haematopoietic stem cell transplantation
Sharma, A., Rath, G. K., Chaudhary, S. P., Thakar, A., Mohanti, B. K., & Bahadur, S. Background Oral mucositis is a common inflammatory complication in patients undergoing high-dose
A Pilot Study on the Efficacy of Lactobacillus Brevis CD2 Lozenges in Preventing Oral Mucositis by High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation
Giammarco, S., Chiusolo, P., Di Giovanni, A., Metafuni, E., Sica, S., Iavarone, F., et al. Abstract Treatment-induced oral mucositis (OM) is a pathological process characterized by mucosal damage,
